Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

ICON shareholders vote in favour of all resolutions at its Extraordinary General Meeting relating to the proposed conversion to a direct listing of ICON’s shares on NASDAQ

ICON
Posted on: 18 Dec 12

ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions recommended by the Board at the Extraordinary General Meeting (“EGM”) of the Company, held on 17th December 2012, were duly passed by shareholders. These resolutions, relating to the proposed conversion to a direct NASDAQ listing for ICON Shares, were set out in the Notice of the EGM sent to shareholders on 16th November 2012 and are available on the ICON plc website.

Forms of Proxy were received before the meeting, appointing proxies and giving them the following voting instructions:

       

TOTAL NUMBEROF PROXIES

 

      VOTE FOR      

VOTEAGAINST

     

VOTEWITHHELD

   
Resolution Number               Number of Votes       Number of Votes       Number of Votes

1

      53,406,101       53,341,438       246       64,417

2**

     

53,406,101

      53,329,851       3,081       73,169

3**

     

53,406,101

      53,009,922       6,211       389,968

** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.

Consequently, the date of delisting from the Irish Stock Exchange is expected to be 30th January 2013 and the expected date of the termination of the current ADR programme is 1st February 2013. The direct trading of ICON Shares on NASDAQ is expected to commence on 4th February 2013.

The information contained in this release is as of 18th December 2012. The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in ICON’s Annual Report for the fiscal year ended December 31, 2011 and in the forms filed with the US Securities and Exchange Commission, including the Forms 20-F, F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.

About ICON plc:

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 82 locations in 40 countries and has approximately 9,430 employees. Further information is available at www.iconplc.com.

SOURCE: ICON plc

ICON/ICLR-F

Business Wire
http://www.businesswire.com/

Last updated on: 18/12/2012

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.